HDL cholesterol efflux capacity and incident cardiovascular events. - Wikidata - awgldk - TriplyDB

HDL cholesterol efflux capacity and incident cardiovascular events.

HDL cholesterol efflux capacity and incident cardiovascular events.

http://www.wikidata.org/entity/Q35021594

about

Stabilization of high-risk plaques High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties CETP Inhibition: Past Failures and Future Hopes Use of fibrates in the metabolic syndrome: A review Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk The role of the lymphatic system in cholesterol transport What does procollagen C-endopeptidase enhancer protein 2 have to do with HDL-cholesteryl ester uptake? Or how I learned to stop worrying and love reverse cholesterol transport?HDL and glucose metabolism: current evidence and therapeutic potential Diagnosis and treatment of high density lipoprotein deficiency Nutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndrome Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?AIBP: A Novel Molecule at the Interface of Cholesterol Transport, Angiogenesis, and Atherosclerosis Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?Novel methodologies for biomarker discovery in atherosclerosis Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.Cardiovascular complications of type 1 diabetes: update on the renal link.Moderate Alcohol Consumption and Chronic Disease: The Case for a Long-Term Trial.Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches.HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation.Liver X Receptors Link Lipid Metabolism and Inflammation.APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity Lipid Lowering Therapy to Modify Plaque Microstructures.Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients.Thermogenic adipocytes promote HDL turnover and reverse cholesterol transport.Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophages ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis.A plant-based diet and heart failure: case report and literature review Saturated Fat Consumption and Risk of Coronary Heart Disease and Ischemic Stroke: A Science Update.Reduced HDL function in children and young adults with type 1 diabetes.Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity.Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.Small HDL promotes cholesterol efflux by the ABCA1 pathway in macrophages: implications for therapies targeted to HDL.A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus.

P2860

Q26738584-31EAA9C2-783D-47DA-A38A-82445D682F32 Q26750603-35E421A6-AB4F-4AC1-8D93-19F9C419F2E6 Q26753158-3191EB3C-135B-407B-881E-CEBB157C2AF1 Q26765234-8BBF587E-7310-4F36-94C8-0469955FD9A5 Q26774903-38EEFDC5-2E04-489E-9CFD-A3B70C2C085B Q26775420-A716F1F3-D42E-41CF-B937-FE3C8CB9F9BF Q26782973-C0E3139E-1EB9-4EA4-ABC8-F0E2E870D18B Q26821862-38233387-170E-4865-A9AB-774B775384D7 Q26996502-554042D1-BF13-4239-B086-3995FE781C1C Q28067479-82F68737-A2BE-4C3C-A45C-95092AF63AE2 Q28079661-82CA0EA9-6734-4850-9204-B8F52F7D03F5 Q28080768-B93BE393-2C11-481B-8348-32502CBDEE86 Q28083058-B356058D-0679-4D08-9EF7-2D5C50B67DE9 Q28083619-B243FC7C-168A-4E1B-8AC5-2FA7553CA065 Q28086787-245CC13C-E881-4CBB-9914-A78DD34F7F00 Q28088373-35007BFC-8728-4D03-8E0E-EB76ED1A7F56 Q30234302-D94B1933-1F9E-4428-BCD2-2CB87D5D9064 Q30239971-9161C288-D796-42A5-90BE-75609C272257 Q30244357-5CC0F87D-6983-4FD2-8407-C175D2BEDE9A Q30251632-356A8213-0834-4169-8367-EADB3114FA79 Q30251918-0BC96B45-8A71-4BE7-AB24-7EE338270184 Q30252316-E5FE74ED-C6DA-4B7D-9B09-A3E102A62044 Q30279056-861FDACC-FA07-4862-AD24-91F7E7955BF7 Q30655573-AC7E4C5E-3691-42B0-8920-B39A2587DECC Q33567290-91F3A7B4-1E7F-402C-9637-4170C9E09B34 Q33572720-BE0FA5F3-154D-42C0-9885-891ACF326F4F Q33587094-A04B4E29-2E03-4014-8216-E8BEAB89A5B2 Q33669547-3A9CEF2B-B790-4B71-8FE9-515E795BA0DD Q33725659-E293F6F5-D2EE-405C-9B3B-FBE9D982FA9E Q33750044-AC607A7C-02DD-4437-9DA8-39D082B56E9A Q33785595-614F22A6-0E70-437A-8C2B-2A8EC063FAC8 Q33810706-B880CAC5-821D-4ED1-A9E4-11D9B6A2EB4D Q33882594-2DBB510B-FAB8-45DD-B081-152B5ED91C02 Q33917580-2A816121-D473-4749-9E81-6A1A84D09E18 Q34521175-1E6D2264-5C70-4F8E-B29A-01B9C6A5C2C8 Q34534212-98846B9B-287D-4949-AC82-71EE5D3AD59E Q35120961-E67ADEBC-A54D-48D6-8BE1-7C97300CD320 Q35135726-32D80FD4-0930-44BC-B5A8-8ABCABE72B5A Q35234656-A7861B72-B942-4A7D-BF02-5AAA0A892AE3 Q35562323-DD799DEB-ED38-449A-899A-24617C673F25

P2860

HDL cholesterol efflux capacity and incident cardiovascular events.

http://www.wikidata.org/entity/Q35021594

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

HDL cholesterol efflux capacity and incident cardiovascular events.

@ast

HDL cholesterol efflux capacity and incident cardiovascular events.

@en

type

label

HDL cholesterol efflux capacity and incident cardiovascular events.

@ast

HDL cholesterol efflux capacity and incident cardiovascular events.

@en

prefLabel

HDL cholesterol efflux capacity and incident cardiovascular events.

@ast

HDL cholesterol efflux capacity and incident cardiovascular events.

@en

P1433

Q35021594-1DC0DAF3-BE4A-49EF-B118-9F0F0281FA88

P1476

Q35021594-140BC31B-58A9-4F30-B36B-331A51D25D8A

P2093

Q35021594-052D9AEE-F32A-45C5-92E1-86729813D0CA

Q35021594-2934EF57-55C5-45D0-A65E-DEFBD1BAEA0C

Q35021594-3A714B95-D220-4E19-8A2A-F51451BD81A8

Q35021594-691A2EDF-5B72-4D73-ACB7-AC6726034103

Q35021594-77E675A4-E1AC-45FE-9980-573E419322A0

Q35021594-78D2C906-1BDE-443A-87A8-E1EC53B36C93

Q35021594-864E7AAA-8008-4929-8514-A9828C8E7109

Q35021594-8DDDB5E0-D7DD-4AB9-B031-2DF75EFA7CD8

Q35021594-93C03B60-EAB6-4F32-A088-73656D860838

Q35021594-9F2AC2BC-7B90-4958-B821-594AF86EE419

P2860

Q35021594-052B5C6D-D7EF-406C-9C2D-A4DB16D8DFEE

Q35021594-10C6EE38-045D-440F-BB26-F973FE0835C0

Q35021594-24C62DD6-73DE-47FF-8A24-491A0DEF4904

Q35021594-2F9C3F93-C297-4B1C-B494-78ED577C6C20

Q35021594-311C5E99-417E-4403-853C-D99C4B86FD0C

Q35021594-31518616-8E57-429B-8E5D-C73962AAB677

Q35021594-3985F7F9-8162-44D9-9A7F-606437C7C056

Q35021594-39897D5F-F5C1-4A5C-8314-852E6BD5F97C

Q35021594-3CE68B0C-4351-452A-9037-CD5B979185A4

Q35021594-43431555-BF64-4A0A-AE02-BE5CE6ABFD4F

P304

Q35021594-52B5FE15-BD19-448A-B7EB-9B0635B354C6

P31

Q35021594-7979B24B-A651-4D98-90E4-BE2D4B1C5087

P356

Q35021594-D4868D9B-4404-4EC0-B9C1-482E95A9F920

P407

Q35021594-8F4284F2-4B99-4F03-8A38-3CFA7EC0DDB2

P433

Q35021594-46EA745C-76ED-410B-B32A-BAB63DAF73DD

P478

Q35021594-52185BBD-8E62-4E04-8850-2DF268649ADC

P577

Q35021594-2C00F1E6-DAD6-46CA-AC51-8FD288FB910B

P698

Q35021594-8F01D80A-93E6-4410-8DB4-45E16113628F

P921

Q35021594-716F4BE0-9D97-42C0-8205-12325FC4DB7D

P932

Q35021594-175A0301-A7DC-4DEC-AD8A-FCFE34D50C71

P356

P1433

The New England Journal of Medicine

P1476

HDL cholesterol efflux capacity and incident cardiovascular events.

@en

P2093

Amit Khera

http://www.w3.org/2001/XMLSchema#string

Anand Rohatgi

http://www.w3.org/2001/XMLSchema#string

Colby R Ayers

http://www.w3.org/2001/XMLSchema#string

Daniel R Rader

http://www.w3.org/2001/XMLSchema#string

Edward G Givens

http://www.w3.org/2001/XMLSchema#string

Ian J Neeland

http://www.w3.org/2001/XMLSchema#string

Ivan S Yuhanna

http://www.w3.org/2001/XMLSchema#string

James A de Lemos

http://www.w3.org/2001/XMLSchema#string

Jarett D Berry

http://www.w3.org/2001/XMLSchema#string

Kyle E Wedin

http://www.w3.org/2001/XMLSchema#string

P2860

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

Effects of torcetrapib in patients at high risk for coronary events

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association

Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling.

The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages.

Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.

P304

2383-2393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1409065

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

371

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25404125

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

4308988

http://www.w3.org/2001/XMLSchema#string